3 completed, 2 withdrawn, 1 terminated. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Withdrawn 2, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow crenolanib: new trials by email Literature Review of crenolanib trials Research Report on crenolanib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia Crenolanib, Fludarabine, Cytarabine - Relapsed/Refractory FLT3-mutated AML | Phase 2 | Withdrawn | Arog Pharmaceuticals, Inc. | 2018-01-01 | 2019-01-10 | |
| Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification crenolanib - Recurrent/Refractory Glioblastoma | Phase 2 | Completed | Arog Pharmaceuticals, Inc. | 11 | 2016-04-01 | 2020-07-20 |
| Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML Crenolanib, Mitoxantrone, Cytarabine - Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Completed | Arog Pharmaceuticals, Inc. | 16 | 2016-02-01 | 2023-12-20 |
| A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations crenolanib, cytarabine, daunorubicin - Newly Diagnosed AML With FLT3 Activating Mutations | Phase 2 | Completed | Arog Pharmaceuticals, Inc. | 44 | 2015-01-01 | 2024-02-02 |
| Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas Crenolanib (CP-868,596) - Glioma | Phase 2 | Terminated | Arog Pharmaceuticals, Inc. | 10 | 2011-04-01 | 2018-07-05 |
| A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel. docetaxel, CP-868,596 + docetaxel, AG-013736 + docetaxel - Carcinoma, Non-Small-Cell Lung | Phase 2 | Withdrawn | Arog Pharmaceuticals, Inc. | 2007-05-01 | 2012-08-09 |
Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Glioblastoma (1) · Glioma (1) · Leukemia, Myeloid, Acute (1) · Recurrence (1)
Arog Pharmaceuticals, Inc. (6)
United States (4)
Barbara O'Brien, MD (1) · Elizabeth Maher, M.D., Ph.D. (1) · Richard Stone, MD (1)